Ratings by UBS (Michael Yee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 3/3/2026 | Nuvation Bio Inc | NUVB | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/27/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
103.24 (98.40) |
-4.69% | Details | |
| 2/25/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | MBX Biosciences Inc | MBX | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Buy) |
64.11 (114.33) |
78.33% | Details | |
| 2/18/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | New Coverage | Buy (N/A) |
29.12 (28.91) |
-0.72% | Details | |
| 2/10/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 2/5/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/2/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 1/15/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 1/13/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/12/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 1/12/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Ventyx Biosciences Inc | VTYX | Downgrade | Neutral (Buy) |
10.05 (14.00) |
39.3% | Details | |
| 1/7/2026 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
220.18 (230.11) |
4.51% | Details | |
| 1/7/2026 | Biogen | BIIB | New Coverage | Neutral (N/A) |
174.63 (184.87) |
5.86% | Details | |
| 1/7/2026 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (Neutral) |
53.06 (60.29) |
13.63% | Details | |
| 1/7/2026 | Gilead Sciences | GILD | New Coverage | Buy (Neutral) |
118.30 (143.93) |
21.67% | Details | |
| 1/7/2026 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
1041.51 (990.33) |
-4.91% | Details | |
| 1/7/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
77.51 (73.05) |
-5.75% | Details | |
| 1/7/2026 | Allogene | ALLO | New Coverage | Buy (N/A) |
1.35 (2.30) |
70.37% | Details | |
| 1/7/2026 | Zai Lab | ZLAB | New Coverage | Buy (N/A) |
18.09 (19.54) |
8.02% | Details | |
| 1/7/2026 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
7.82 (10.05) |
28.52% | Details | |
| 1/7/2026 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
30.20 (28.34) |
-6.16% | Details | |
| 1/7/2026 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
42.76 (45.29) |
5.92% | Details | |
| 1/7/2026 | Schrodinger | SDGR | New Coverage | Neutral (N/A) |
18.50 (12.74) |
-31.14% | Details | |
| 1/7/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.74 (3.79) |
1.34% | Details | |
| 1/7/2026 | Oruka Therapeutics | ORKA | New Coverage | Buy (N/A) |
26.88 (32.97) |
22.66% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
25.10 (21.55) |
-14.14% | Details | |
| 1/7/2026 | Nuvation Bio Inc | NUVB | New Coverage | Neutral (N/A) |
8.59 (4.59) |
-46.57% | Details | |
| 1/7/2026 | MBX Biosciences Inc | MBX | New Coverage | Buy (N/A) |
29.31 (30.55) |
4.23% | Details | |
| 1/7/2026 | Kodiak Sciences Inc. | KOD | New Coverage | Buy (N/A) |
25.00 (24.86) |
-0.56% | Details | |
| 1/7/2026 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
4.60 (6.13) |
33.26% | Details | |
| 1/7/2026 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
32.75 (32.94) |
0.58% | Details | |
| 1/7/2026 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
34.94 (33.19) |
-5.01% | Details | |
| 1/7/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
16.02 (19.69) |
22.91% | Details | |
| 1/7/2026 | Cogent | COGT | New Coverage | Buy (N/A) |
34.26 (37.08) |
8.23% | Details | |
| 1/7/2026 | Beam Therapeutics Inc | BEAM | New Coverage | Neutral (N/A) |
26.84 (26.54) |
-1.12% | Details | |
| 1/7/2026 | AnaptysBio | ANAB | New Coverage | Buy (N/A) |
43.20 (55.41) |
28.26% | Details | |
| 1/7/2026 | Aligos Therapeutics Inc. | ALGS | New Coverage | Buy (N/A) |
8.41 (6.98) |
-17% | Details | |
| 1/7/2026 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
61.83 (64.11) |
3.69% | Details | |
| 1/7/2026 | Pfizer | PFE | New Coverage | Neutral (N/A) |
25.17 (27.05) |
7.47% | Details | |
| 1/6/2026 | Amgen | AMGN | New Coverage | Buy (N/A) |
320.72 (369.53) |
15.22% | Details |
